b'Appendices Appendix 4 GENOME CANADA Statement of Operations and Changes in Net AssetsYear ended March 31, 2019, with comparative information for 2018 (in thousands of dollars)20192018Revenue: Amortization of deferred contributionsresearch projects$68,054$69,558 Amortization of deferred contributions related to capital assets (note 6)1654 68,07069,612Expenses: Projects and Genome Centres61,97763,247 Program management1,7322,184 Strategy, development and external relations1,9281,547 Corporate services2,4172,580 Amortization of capital assets1654 68,07069,612Excess of revenue over expenses,being net assets, end of year$$ See accompanying notes to financial statements.55'